Skip to content

Study · Randomized controlled trial · n = 42 · 2006

5 results

[Prevention and management of lung infections with thymosin alpha1 in critical patients with tracheotomy].

Huang DP, Yang M, Peng WP, Chen XS, Chen ZQ

Nan fang yi ke da xue xue bao = Journal of Southern Medical University1 Jan 2006Cited by 3 (Europe PMC)

PMID16495194 (opens in a new tab)PepBankPUB-16495194
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In critical patients with tracheotomy, thymosin alpha(1) lowered the lung infection rate compared with saline.

    In plain wordsIn critically ill patients with a tracheotomy, lung infections were less frequent with thymosin alpha‑1 than with saline.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLung infection rate
    Study

    n = 42

    Comparator
    Saline
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    11.6 mg daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
    1 context sentence
    Summary · context
    Forty-two patients were randomly divided into treatment group and control group to receive daily subcutaneous thymosin injection at 11.6 mg and saline of 2 ml for 7 days, respectively.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In critical patients with tracheotomy, thymosin alpha(1) lowered white blood cell count compared with saline.

    In plain wordsIn critically ill patients with a tracheotomy, white blood cell counts were lower with thymosin alpha‑1 than with saline.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseWhite blood cell count
    Study

    n = 42

    Comparator
    Saline
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    11.6 mg daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
    1 context sentence
    Summary · context
    Forty-two patients were randomly divided into treatment group and control group to receive daily subcutaneous thymosin injection at 11.6 mg and saline of 2 ml for 7 days, respectively.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In critical patients with tracheotomy, thymosin alpha(1) lowered C-reactive protein compared with saline.

    In plain wordsIn critically ill patients with a tracheotomy, C-reactive protein was lower with thymosin alpha‑1 than with saline.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseC-reactive protein
    Study

    n = 42

    Comparator
    Saline
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    11.6 mg daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
    1 context sentence
    Summary · context
    Forty-two patients were randomly divided into treatment group and control group to receive daily subcutaneous thymosin injection at 11.6 mg and saline of 2 ml for 7 days, respectively.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In critical patients with tracheotomy, thymosin alpha(1) lowered tumor necrosis factor-alpha compared with saline.

    In plain wordsIn critically ill patients with a tracheotomy, TNF-alpha was lower with thymosin alpha‑1 than with saline.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTumor necrosis factor-alpha
    Study

    n = 42

    Comparator
    Saline
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    11.6 mg daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
    1 context sentence
    Summary · context
    Forty-two patients were randomly divided into treatment group and control group to receive daily subcutaneous thymosin injection at 11.6 mg and saline of 2 ml for 7 days, respectively.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In critical patients with tracheotomy, thymosin alpha(1) lowered interleukin-6 compared with saline.

    In plain wordsIn critically ill patients with a tracheotomy, interleukin-6 was lower with thymosin alpha‑1 than with saline.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInterleukin-6
    Study

    n = 42

    Comparator
    Saline
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    11.6 mg daily · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with the control group, the infection rate, white blood cell count, C-reactive protein, tumor necrosis factor-alpha and interleukiu-6 were significantly lower in the treatment group.
    1 context sentence
    Summary · context
    Forty-two patients were randomly divided into treatment group and control group to receive daily subcutaneous thymosin injection at 11.6 mg and saline of 2 ml for 7 days, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.